

**STUDENT NAME:** Tyler Burnside

## **Network Meta-Analysis of Perioperative Nutrition**

**PROJECT TITLE:** Does perioperative nutrition improve clinical outcomes in patients undergoing upper gastrointestinal surgery?: A network meta-analysis

**STUDENT'S NAME:** Tyler Burnside **SUPERVISOR'S NAME:** Dr. Sadeesh Srinathan

**DEPARTMENTAL AFFILIATIONS:** Department of Surgery

### **SUMMARY:**

Each year in Canada, more than 2000 patients undergo surgical resection for treatment of esophageal, pancreatic, or stomach cancer. However, resection of upper gastrointestinal malignancies is associated with significant mortality and morbidity. One reason for the high rate of complications in this population of patients is preoperative malnutrition. To counteract the effects of malnutrition, post-operative nutritional support is often provided to these patients. Nutrition can be provided directly into the central circulation by total parenteral nutrition (TPN) or into the GI tract via a nasojejun tube (a catheter passed through the nose into the small bowel) or a surgically placed jejunostomy tube (through the anterior abdominal wall and into the small bowel). It remains unclear which method of nutrient delivery, if any, provides the best overall patient outcomes. For this reason we have undertaken a network meta-analysis to evaluate the effects of the various perioperative nutritional delivery methods on clinical outcomes in patients undergoing upper gastrointestinal surgery.


### **ACKNOWLEDGEMENTS:**

We gratefully acknowledge the support entirely or in part by the following sponsors;


CIHR, Dr. H.T. Thorlakson Foundation, MMSF, MHRC, Associate Dean (Research), Faculty of Medicine, St. Boniface Research Foundation and the Health Sciences Centre Research Foundation.

Dr. Srinathan's research is supported by the Rudy Falk Clinician Scientist Award.

We gratefully acknowledge our co-authors for their contributions: Kristian Thorlund, Tamara Hamin, Michael Johnston, and Tania Gottschalk.



Student's Signature



Supervisor's Signature

## **Introduction:**

Each year in Canada, more than 2000 patients undergo surgical resection for treatment of esophageal, pancreatic or stomach cancer (1, 2). However, resection of upper gastrointestinal (GI) malignancies is associated with significant mortality and morbidity. Recent cohort studies have estimated the rates of mortality and morbidity associated with esophageal resection to be 9.8% and 49.5%, respectively (3). Gastrectomies had rates of 7.6% and 33.3% (4), while pancreatectomies had rates of 3.8% and 33.8% (5).

One reason for the high rate of complications in this population of patients is preoperative malnutrition. Significant weight loss of greater than 10% is seen in 20-30% of patients undergoing resection of upper GI malignancies (4-6). This situation is made worse by the starvation that occurs in the postoperative period, since patients typically remain without oral intake for 7 days after surgery to allow for the anastomosis to heal and the integrity of the GI tract to be re-established.

To counteract the effects of malnutrition, post-operative nutritional support is often provided to these patients. Nutrition can be provided directly into the central circulation by total parenteral nutrition (TPN) or into the GI tract via a nasojejun tube (a catheter passed through the nose into the small bowel) or a surgically placed jejunostomy tube (through the anterior abdominal wall and into the small bowel). Enteral nutritional compounds are available as either “standard” formulation or “immune enhanced” formulation.

Although there is evidence that nutritional support improves laboratory markers of immune function (7, 8), it remains unclear if this results in meaningful improvements in clinical outcomes (9, 10).

In a literature review of critically ill patients McCave and Heyland found that enteral nutrition enhances immune function and results in improved outcomes. However, this effect is not as evident with parenteral nutrition (8). As their study only includes critically ill patients with a variety of disease states, it is questionable if their findings remain valid for patients undergoing elective operations.

Although it is unclear whether nutritional support provides a clinical benefit, there are clear risks associated with providing nutrition. TPN and enteral nutrition both have complications that can range from troublesome to life threatening (11-18).

Most studies that have addressed the issue of perioperative nutrition have assumed that nutritional support is beneficial and compared one form of intervention to another. There have been few studies of sufficient size to answer the most fundamental question: Does perioperative nutritional support of any kind lead to improved clinical outcomes?

There are many options for providing nutritional support. In a primary review of the literature we were able to identify seven types of interventions: 1) fluid hydration alone, 2) standard enteral formulation delivered via nasojejun tubes, 3) standard enteral nutrition delivered via a jejunostomy tube, 4) enhanced enteral formulation delivered via a nasojejun tube, 5) enhanced

enteral formulation delivered via a jejunostomy tube, 6) standard total parenteral nutrition, and 7) enhanced total parenteral nutrition. This leads to twenty-one possible two-armed comparisons, but previous meta-analyses have studied only a subset of the possible comparisons.

Previous studies have combined data from patients undergoing a variety of types of GI surgery, including colorectal, despite the fact that these patients have different risk profiles and outcomes that are likely to affect the conclusions. For example, Drolet found that in a study of 54,000 patients in the US, patients undergoing elective colorectal surgery presented with malnutrition rates of 4-6% and had a mortality rate of 3.1%, compared to 20-30% and 10% for those undergoing upper GI surgery (19).

Previous studies have also neglected to consider the route of nutritional delivery despite the likely differences in possible complications from each method.

For this study, we undertook a multiple-treatment comparison using a network meta-analysis in order to incorporate the entire evidence base on effectiveness of nutritional interventions. We limited the study to upper GI resections to maintain a consistent risk profile and took route of nutritional delivery into consideration.

Network meta-analysis is a relatively new statistical technique that allows for integration of direct (head-to-head) comparisons and control (i.e., fluid hydration alone) comparisons. It also permits inferences into the relative efficacy of treatments that may not have been compared to each other in direct randomized control trials. Network meta-analysis therefore provides a clinically useful synthesis that can help guide treatment decisions (20-27).

## **Objective**

The primary objective of this study was to determine if patients undergoing surgical resection and reconstruction of the upper GI tract for carcinoma benefit from nutritional support provided in the first seven days after surgery.

## **Methods**

We performed a systematic review and a network meta-analysis of randomized control trials. Studies were required to meet four inclusion criteria to be considered in the review: 1) reports on adult patients undergoing elective esophagectomy, gastrectomy, or pancreatectomy for resection of upper GI carcinoma, 2) is a randomized control trial, 3) compares at least two nutritional interventions that were delivered during the first seven days after surgery, and 4) reports at least one of our outcomes of interest.

*Search strategy:* A search strategy incorporating key terms and MeSH headings (see Appendix 1) was performed in June, 2011 across the following well-known databases: PubMed (MEDLINE); SCOPUS; Web of Knowledge; EMBASE; and the Cochrane Library. When possible, filters employed in search strategies across the various databases attempted to retrieve randomized controlled trials appearing in journals and conference proceedings. As noted in the appendix, the date ranges searched varied depending on database coverage.

*Selection of studies:* We merged the electronic search results using RefWorks, a reference management software suite, and removed duplicate reports. The search yielded 936 studies, for which two reviewers examined the titles and abstracts. A study was included for full-text review if either reviewer considered it relevant according to the inclusion and exclusion criteria. Two reviewers independently reviewed the 191 full texts of the retrieved articles for inclusion using the specified criteria, which resulted in 26 included studies (Figure 1). Disagreements were resolved by discussion or by a third independent reviewer.

*Data extraction and management:* After a final decision on inclusion, assessment of methodological quality (risk of bias) and data for the specified outcomes were extracted independently by two reviewers into a custom electronic database created using FileMaker Pro 11 (FileMaker Inc. Santa Clara, USA). Further information including details on study design, participants, interventions, and follow-up were also extracted. Authors were contacted if there was a need for additional information. Discrepancies were discussed until a consensus was reached and further unresolved issues were passed to a third reviewer.

*Sources of bias:* The risk of bias in the included studies was assessed and reported using the method outlined in the Cochrane Handbook Chapter 8, Section 8.5 (28). A summary of the risk of bias across studies was created using a risk of bias summary figure (Figure 2).

*Assessment of heterogeneity:* We found there to be too few studies in each possible pairwise comparison to determine sources of heterogeneity. Therefore we only report the  $I^2$  as a measure of heterogeneity.

*Data synthesis:* We performed a standard fixed-effect meta-analysis to determine the odds ratios and 95% confidence intervals for each of five primary outcomes 1) 30-day mortality, 2) anastomotic failure, 3) sepsis, 4) pulmonary infections, and 5) total infections. A continuity correction was required for events that occurred zero times in various studies. This was accomplished by the addition of 0.5 to each value where there were zero events reported. Next, a fixed-effect network meta-analysis within a Bayesian framework was undertaken (Figure 3).

For all analyses we used no nutritional intervention, i.e. intravenous hydration only prior to oral intake, as the reference standard.

*Sensitivity analysis:* Sensitivity analysis was carried out to determine how the effect size estimates varied according to the method selected for dealing with zero events. We found that the estimate of the effect remained similar across these analyses regardless of the continuity correction method used (exclude studies with zero events, use of 0.5 for continuity corrections, and use of 0.01 for continuity corrections).

## **Results**

There were 26 studies included in this review (29-54)(Table 1a). The raw agreement for inclusion was 91.6% and the Kappa was 0.76, which indicates excellent agreement for inclusion. There were 34 papers for which we are in the process of acquiring further information (require translation, or clarification by author).

The 26 studies reported on 2452 patients of whom 31% underwent esophagectomy, 38% underwent gastrectomy, and 25% underwent pancreatectomy (Table 1b). The mean age of the patients was 64.6 years. The median mortality rate reported across the studies was 2.30% with an interquartile range of 0.00% to 2.98%. The median and interquartile range for anastomotic failure, sepsis, pulmonary infection and total infections was 8.25% (4.43-13.33%), 4.55% (3.08-5.78%), 13.8% (7.7-22.4%), and 23.1% (17.5-39.6%) respectively (Table 2).

The trials ranged from 20-257 participants with the median number of participants being 68.5. There were two studies with more than 200 participants and nine having less than 50 participants (Table 1a).

Only 38% (10/26) of studies reported the number of patients who had significant weight loss prior to surgery. Of the 10 studies that did report this information, a median of 29.5% (range 17% to 54%) of patients had significant (>10%) weight loss (Table 1b).

Most studies were not blinded, given the nature of the interventions. However, 54% of the studies were at low risk of bias for adequate concealment of allocation and 62% were at low risk of bias for intention to treat analysis (Figure 2).

We combined standard and immune enhanced forms of nutrition delivery to increase the power of the analysis. To test the assumption that these were sufficiently similar to combine we performed a preliminary analysis where standard and enhanced nutrition were considered separately. We found very similar results between the two for all outcomes except total rate of infection, which appeared to favor enhanced (Table 3).

For the primary outcome of mortality, the network meta-analysis odds ratio estimates suggested that the use of either standard or enhanced nutrition delivered via jejunostomy was associated with an elevated risk of death (odds ratio of 1.44, 95% CI (0.34, 5.10)). The odds ratio estimates also suggested that enteral nutrition delivered by a nasojejunal tube and TPN lead to decreased mortality (odds ratios of 0.44 (0.10, 1.59) and 0.22 (0.04, 0.94), respectively). However, considerable uncertainty is associated with these estimates due to the limited number of deaths in the included trials. All interventions appeared to decrease the risk of anastomotic failure, albeit not significantly. The odds ratio estimates for nutrition delivered via jejunostomy suggested a more pronounced risk reduction than for the other interventions. For sepsis, the odds ratio estimates suggested a decreased risk with jejunostomy, but an increased risk with nasojejunal tube and TPN. However, considerable uncertainty surrounds these estimates due to a very limited number of events and trials informing this outcome. Jejunostomy, nasojejunal, and TPN all produced similar odds ratio estimates (and beneficial effects) for pulmonary infection (odds ratios of 0.33 (0.13, 0.74), 0.44 (0.15, 1.19), and 0.40 (0.13, 1.11), respectively). Lastly, jejunostomy and nasojejunal tube were associated with a decrease in total reported infections (odds ratios of 0.68 (0.44, 1.07) and 0.82 (0.43, 1.49), respectively), whereas TPN did not appear to reduce the proportion of total reported infections (1.04 (0.57, 1.89)) (Table 3)(Figure 4).

When we undertook direct comparisons, certain point estimates were somewhat inconsistent with those of the network meta-analyses. However, the wide confidence intervals and the potential for

Type-I errors due to multiple testing may explain these discrepancies. We therefore felt comfortable combining all trials in the network meta-analysis.

## Discussion

*Main results:* We carried out a systematic review and a network meta-analysis of randomized control trials to determine the effect of perioperative nutritional support in patients undergoing resection and reconstruction of upper gastrointestinal cancer.

We found 26 studies including 2452 patients. The studies were generally small and often did not report the degree of weight loss in their study populations. The number of events reported in the studies was small, and a large number reported no events for some of their outcomes, reflecting the relatively low overall event rate.

The overall trend is that perioperative nutritional support is associated with a decreased risk of anastomotic failure, sepsis, pulmonary infections and total infections when compared to no nutritional support. For these outcomes there does not appear to be any significant differences between enteral nutrition, delivered by nasojejunal tube or surgical jejunostomy, and TPN. However, there is a suggestion that mortality is elevated when a surgical jejunostomy tube is used. In Canada, the primary method for providing nutrition to this patient population is the jejunostomy tube, which makes the suggestion of increased mortality particularly concerning. The potentially significant complications attributable to this means of nutritional delivery have been suggested in the past (55, 56).

The potential benefits ascribed to perioperative nutritional support may well be true given our findings, but the width of the confidence intervals around our estimates brings into question the strength of this evidence. We expected to find more robust evidence for the benefit of perioperative nutrition as we limited our study to patients at relatively high risk of adverse events and thus were more likely to benefit from an intervention if it were effective. Instead, we found that the benefits of perioperative nutrition methods were not convincing, despite their wide use. These findings are similar to that reported in previous meta-analyses by Lewis and Mazaki (9, 18).

Clearly, there are a large number of factors that would account for the wide confidence intervals and uncertainty of effect. There is likely to be clinical heterogeneity and differing outcome definitions across the included studies even with the small values for  $I^2$  seen in the analysis.

The variation in the proportion of patients with >10% weight loss is one likely reason for heterogeneity. Significant weight loss is a strong predictor of morbidity and mortality after upper GI surgery (4, 57). Due to the small number of studies in each of the comparisons and the number of studies where this information was actually available (10/26 studies), we were unable to undertake a formal subgroup analysis based on this factor. However, the variation in the proportion of patients with significant weight loss (17-54%) is noticeable (Table 1b).

We noted that there were some inconsistencies between the estimates given by the standard meta-analysis and the network meta-analysis. This could be accounted for by the wide confidence intervals around the estimates from both methods. Another reason for the differential estimates is that by design, the network meta-analysis gains information from the indirect comparisons that is likely to alter the estimates. Since a major reason for undertaking a network meta-analysis was the expectation that the pairwise comparisons were likely to be few, the extra information from the indirect comparisons is beneficial.

*Strengths of this study:* As far as we are aware, this is the only systematic review that specifically addresses the question of perioperative nutritional support in patients undergoing upper gastrointestinal surgery. Patients with upper GI malignancies are more likely to be malnourished, as they undergo a generally more significant surgical insult and experience a longer period of limited oral intake. All of these factors should lead to a higher event rate and if an intervention is effective it should be more apparent in this population. Previous systematic reviews have included patients undergoing other types of gastrointestinal surgery that generally have a lower risk of the major outcomes that we were concerned with.

Using network meta-analysis we were able to include all interventions and comparisons, which has not been done previously. This strategy also deals with a potential source of bias in systematic reviews and meta-analysis where the conclusions are drawn from only a certain subset of possible comparisons.

Previous meta-analyses have not taken into consideration the route of nutritional delivery. Given the different risk profiles of the three routes of delivery, we feel that this is an important consideration.

*Limitation of this study:* Like all systematic reviews, this is ultimately an observational study and is therefore subject to inherent bias. We took care to undertake a wide search and did not exclude on the basis of language. However, due to time constraints, there are a number of studies which may be eligible for inclusion but for which do not have sufficient information at this time.

## **Conclusions**

This study demonstrated that the evidence for the routine use of perioperative nutritional support in patients undergoing upper GI surgery is suggestive but weak. The effect size is credible, but the confidence intervals are wide. The increased risk of mortality in patients receiving nutritional support through a jejunostomy is concerning.

It seems that the role of perioperative nutrition in the setting of upper GI surgery is not settled. There are no trials of sufficient size or of adequate design to address this question and further small studies are unlikely to change the situation. This is the third systematic review that has tried to address this issue and the third study that has come to a similarly tentative conclusion.

A large and well-designed randomized trial is required to clarify the situation. The trial should compare the effect of enteral nutrition delivered by a nasojejunal tube, enteral nutrition delivered

by jejunostomy, and no early nutrition. The study should also be of sufficient size to allow for stratification based on the degree of weight loss.

Given the significant number of patients who undergo upper GI surgery for carcinoma each year in Canada, determining an optimal nutritional management strategy is critical.



## Appendix 1: Database Search Strategies and Date Coverage

### PubMed (MEDLINE) Search – 1949- June 2011

MeSH Terms: enteral nutrition, jejunostomy, nutritional sciences, “surgical procedures, operative”, general surgery, reconstructive surgical procedures, esophagus, esophageal diseases, stomach, neoplasms, carcinoma

Search Terms: enteral nutrition, enteral feeding, perioperative, jejunostomy, nasojejunal, nutritional sciences, nutritional management, nutritional support, surgery, surgical procedures, general surgery, resection, reconstructive surgical procedures, reconstruction, esophagus, esophageal diseases, stomach, upper gastrointestinal, neoplasms, cancer, carcinoma

Limits: Humans Type of Article: Clinical Trial, Meta-analysis, Practice guideline, Randomized control trial, review, comparative study

### EMBASE (OvidSP) – 1974 – June 2011

#1 (neoplasm\* or cancer\* or carcinoma\* or adenocarcinoma\*)

#2 (esophagus or esophageal or "upper gastrointestinal" or stomach or oesophagus or oesophageal)

#3 (surger\* or "surgical procedures" or "surgical procedure" or reconstruct\* or resect\*)

#4 ("enteral nutrition" or "enteral feeding" or "jejunostomy feeding" or "jejunostomy tube" or "jejunostomy tubes" or "nasojejunal feeding" or "nasojejunal tube" or "nasojejunal tubes" or "nutritional support" or "nutritional management" or "perioperative nutrition" or "nutritional sciences")

Title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, and drug manufacturer names were searched

### Web of Knowledge (Thomson Reuters) 1864- June 2011

#1 TS=("enteral nutrition" or "enteral feeding" or "jejunostomy feeding" or "jejunostomy tube" or "jejunostomy tubes" or "nasojejunal feeding" or "nasojejunal tube" or "nasojejunal tubes" or "nutritional support" or "nutritional management" or "perioperative nutrition" or "nutritional sciences")

#2 TS=(surger\* or "surgical procedures" or "surgical procedure" or reconstruct\* or resect\*)

#3 TS=(esophagus or esophageal or "upper gastrointestinal" or stomach or oesophagus or oesophageal)

#4 TS=(neoplasm\* or cancer\* or carcinoma\* or adenocarcinoma\*)

### Cochrane Library (John Wiley and Sons)

#1 (neoplasm\* or cancer\* or carcinoma\* or adenocarcinoma\*) Search All Text

#2 (esophagus or esophageal or "upper gastrointestinal" or stomach or oesophagus or oesophageal) Search All Text

#3 (surger\* or "surgical procedures" or "surgical procedure" or reconstruct\* or resect\*) Search All Text

#4 ("enteral nutrition" or "enteral feeding" or "jejunostomy feeding" or "jejunostomy tube" or "jejunostomy tubes" or "nasojejunal feeding" or "nasojejunal tube" or "nasojejunal tubes" or "nutritional support" or "nutritional management" or "perioperative nutrition" or "nutritional sciences") Search All Text

SCOPUS (Elsevier) - 2004 – June 2011

#1 TITLE-AB-Key(neoplasm\* or cancer\* or carcinoma\* or adenocarcinoma\*)

#2 TITLE-AB-Key(esophagus or esophageal or "upper gastrointestinal" or stomach or oesophagus or oesophageal)

#3 TITLE-AB-Key(surger\* or "surgical procedures" or "surgical procedure" or reconstruct\* or resect\*)

#4 TITLE-AB-Key("enteral nutrition" or "enteral feeding" or "jejunostomy feeding" or "jejunostomy tube" or "jejunostomy tubes" or "nasojejunal feeding" or "nasojejunal tube" or "nasojejunal tubes" or "nutritional support" or "nutritional management" or "perioperative nutrition" or "nutritional sciences")

## References

1. [Internet]. Available from: <http://seer.cancer.gov/statfacts/html/stomach.html>.
2. Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2010. Toronto: Canadian Cancer Society; 2010.
3. Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, et al. Outcomes after esophagectomy: A ten-year prospective cohort. *Ann Thorac Surg*. 2003 discussion 222; Jan;75(1):217-22.
4. Grossmann EM, Longo WE, Virgo KS, Johnson FE, Oprian CA, Henderson W, et al. Morbidity and mortality of gastrectomy for cancer in department of veterans affairs medical centers. *Surgery*. 2002 May;131(5):484-90.
5. Glasgow RE, Jackson HH, Neumayer L, Schifftner TL, Khuri SF, Henderson WG, et al. Pancreatic resection in veterans affairs and selected university medical centers: Results of the patient safety in surgery study. *J Am Coll Surg*. 2007 Jun;204(6):1252-60.
6. Mariette C, Taillier G, Van Seuning I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. *Ann Thorac Surg*. 2004 Oct;78(4):1177-83.
7. Kudsk KA. Current aspects of mucosal immunology and its influence by nutrition. *Am J Surg*. 2002 Apr;183(4):390-8.
8. McClave SA, Heyland DK. The physiologic response and associated clinical benefits from provision of early enteral nutrition. *Nutr Clin Pract*. 2009 Jun-Jul;24(3):305-15.
9. Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: Systematic review and meta-analysis of controlled trials. *BMJ*. 2001 Oct 6;323(7316):773-6.
10. Wheble GA, Benson RA, Khan OA. Is routine postoperative enteral feeding after oesophagectomy worthwhile? *Interact Cardiovasc Thorac Surg*. 2012 Jun 29.
11. Rhee P, Hadjizacharia P, Trankiem C, Chan L, Salim A, Brown C, et al. What happened to total parenteral nutrition? the disappearance of its use in a trauma intensive care unit. *J Trauma*. 2007 Dec;63(6):1215-22.
12. Smith-Choban P, Max MH. Feeding jejunostomy: A small bowel stress test?. *Am J Surg*. 1988 Jan;155(1):112-7.
13. Watters JM, Kirkpatrick SM, Norris SB, Shamji FM, Wells GA. Immediate postoperative enteral feeding results in impaired respiratory mechanics and decreased mobility. *Ann Surg*. 1997 discussion 377-80; Sep;226(3):369-77.
14. Heslin MJ, Latkany L, Leung D, Brooks AD, Hochwald SN, Pisters PW, et al. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. *Ann Surg*. 1997 discussion 577-80; Oct;226(4):567-77.
15. Hayashi JT, Wolfe BM, Calvert CC. Limited efficacy of early postoperative jejunal feeding. *Am J Surg*. 1985 Jul;150(1):52-7.

16. Zapas JL, Karakozis S, Kirkpatrick JR. Prophylactic jejunostomy: A reappraisal. *Surgery*. 1998 discussion 719-20; Oct;124(4):715-9.
17. Lobo DN, Williams RN, Welch NT, Aloysius MM, Nunes QM, Padmanabhan J, et al. Early postoperative jejunostomy feeding with an immune modulating diet in patients undergoing resectional surgery for upper gastrointestinal cancer: A prospective, randomized, controlled, double-blind study. *Clin Nutr*. 2006 Oct;25(5):716-26.
18. Mazaki T, Ebisawa K. Enteral versus parenteral nutrition after gastrointestinal surgery: A systematic review and meta-analysis of randomized controlled trials in the english literature. *J Gastrointest Surg*. 2008 Apr;12(4):739-55.
19. Drolet S, MacLean AR, Myers RP, Shaheen AA, Dixon E, Buie WD. Elective resection of colon cancer by high-volume surgeons is associated with decreased morbidity and mortality. *J Gastrointest Surg*. 2011 Apr;15(4):541-50.
20. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. *BMJ*. 2005 Oct 15;331(7521):897-900.
21. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. *Lancet*. 2009 Feb 28;373(9665):746-58.
22. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. *Stat Med*. 2009 Jun 30;28(14):1861-81.
23. Gartlehner G, Moore CG. Direct versus indirect comparisons: A summary of the evidence. *Int J Technol Assess Health Care*. 2008 Spring;24(2):170-7.
24. Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med*. 2002 Aug 30;21(16):2313-24.
25. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. *J Clin Epidemiol*. 2008 May;61(5):455-63.
26. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: Survey of published systematic reviews. *BMJ*. 2009 Apr 3;338:b1147.
27. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. *Pharmacoeconomics*. 2008;26(9):753-67.
28. Higgins J, Green S., editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0 [updated March 2011] ed. The Cochrane Collaboration; 2011.
29. A Hytander, I Bosaeus, J Svedlund, B Liedman, I Hugosson, O Wallengren, et al. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: A randomized study. In: *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. ; 2005. p. 466-74.
30. Aiko S, Yoshizumi Y, Matsuyama T, Sugiura Y, Maehara T. Influences of thoracic duct blockage on early enteral nutrition for patients who underwent esophageal cancer surgery. *Jpn J Thorac Cardiovasc Surg*. 2003 Jul;51(7):263-71.
31. AM Ryan, JV Reynolds, L Healy, M Byrne, J Moore, N Brannelly, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: Results of a double-blinded randomized controlled trial. In: *Annals of surgery*. ; 2009. p. 355-63.
32. AS Kenler, WS Swails, DF Driscoll, SJ DeMichele, B Daley, TJ Babineau, et al. Early enteral feeding in postsurgical cancer patients. fish oil structured lipid-based polymeric formula versus a standard polymeric formula. In: *Annals of surgery*. ; 1996. p. 316-33.
33. Barlow R, Price P, Reid TD, Hunt S, Clark GWB, Havard TJ, et al. Prospective multicentre randomised controlled trial of early enteral nutrition for patients undergoing major upper gastrointestinal surgical resection. *Clinical Nutrition*.
34. Braga M, Gianotti L, Gentilini O, Parisi V, Salis C, Di Carlo V. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. *Crit Care Med*. 2001 Feb;29(2):242-8.
35. Braga M, Vignali A, Gianotti L, Cestari A, Profili M, Di Carlo V. Benefits of early postoperative enteral feeding in cancer patients. *Infusionsther Transfusionsmed*. 1995 Oct;22(5):280-4.
36. Cooper SC, Hulley CM, Grimley CE, Howden J, McCluskey K, Norton RN, et al. Perioperative peripheral parenteral nutrition for patients undergoing esophagectomy for cancer: A pilot study of safety, surgical, and nutritional outcomes. *Int Surg*. 2006 Nov-Dec;91(6):358-64.
37. Daly JM, Lieberman MD, Goldfine J, Shou J, Weintraub F, Rosato EF, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: Immunologic, metabolic, and clinical outcome. *Surgery*. 1992 Jul;112(1):56-67.

38. Farreras N, Artigas V, Cardona D, Rius X, Trias M, Gonzalez JA. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. *Clin Nutr.* 2005 Feb;24(1):55-65.
39. Giger U, Buchler M, Farhadi J, Berger D, Husler J, Schneider H, et al. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study. *Ann Surg Oncol.* 2007 Oct;14(10):2798-806.
40. Han-Geurts IJM, Hop WC, Verhoef C, Tran KTC, Tilanus HW. Randomized clinical trial comparing feeding jejunostomy with nasoduodenal tube placement in patients undergoing oesophagectomy. *Br J Surg.* 2007 JAN;94(1):31-5.
41. Heslin MJ, Latkany L, Leung D, Brooks AD, Hochwald SN, Pisters PW, et al. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. *Ann Surg.* 1997 Oct;226(4):567,77; discussion 577-80.
42. Heylen AM, Lybeer MB, Penninckx FM, Kerremans RP, Frost PG. Parenteral versus needle jejunostomy nutrition after total gastrectomy. *Clinical Nutrition.* 1987;6(3):131-6.
43. JV Reynolds, S Kanwar, FK Welsh, AC Windsor, P Murchan, GR Barclay, et al. 1997 harry M. vars research award. does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? In: *JPEN. Journal of parenteral and enteral nutrition.* ; 1997. p. 196-201.
44. Kamei H, Hachisuka T, Nakao M, Takagi K. Quick recovery of serum diamine oxidase activity in patients undergoing total gastrectomy by oral enteral nutrition. *Am J Surg.* 2005 Jan;189(1):38-43.
45. Klek S, Kulig J, Sierzega M, Szczepanek K, Szybinski P, Scislo L, et al. Standard and immunomodulating enteral nutrition in patients after extended gastrointestinal surgery--a prospective, randomized, controlled clinical trial. *Clin Nutr.* 2008 Aug;27(4):504-12.
46. Klek S, Kulig J, Sierzega M, Szybinski P, Szczepanek K, Kubisz A, et al. The impact of immunostimulating nutrition on infectious complications after upper gastrointestinal surgery: A prospective, randomized, clinical trial. *Ann Surg.* 2008 Aug;248(2):212-20.
47. Lobo DN, Williams RN, Welch NT, Aloysius MM, Nunes QM, Padmanabhan J, et al. Early postoperative jejunostomy feeding with an immune modulating diet in patients undergoing resectional surgery for upper gastrointestinal cancer: A prospective, randomized, controlled, double-blind study. *Clin Nutr.* 2006 Oct;25(5):716-26.
48. Page RD, Oo AY, Russell GN, Pennefather SH. Intravenous hydration versus naso-jejunal enteral feeding after esophagectomy: A randomised study. *Eur J Cardiothorac Surg.* 2002 Nov;22(5):666-72.
49. Sakurai Y, Masui T, Yoshida I, Tonomura S, Shoji M, Nakamura Y, et al. Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. *World J Surg.* 2007 Nov;31(11):2150,7; discussion 2158-9.
50. Sand J, Luostarinen M, Matikainen M. Enteral or parenteral feeding after total gastrectomy: Prospective randomised pilot study. *Eur J Surg.* 1997 Oct;163(10):761-6.
51. Seike J, Tangoku A, Yuasa Y, Okitsu H, Kawakami Y, Sumitomo M. The effect of nutritional support on the immune function in the acute postoperative period after esophageal cancer surgery: Total parenteral nutrition versus enteral nutrition. *Journal of Medical Investigation.* 2011;58(1-2):75-82.
52. Senkal M, Mumme A, Eickhoff U, Geier B, Spath G, Wulfert D, et al. Early postoperative enteral immunonutrition: Clinical outcome and cost-comparison analysis in surgical patients. *Crit Care Med.* 1997 Sep;25(9):1489-96.
53. Senkal M, Zumbel V, Bauer KH, Marpe B, Wolfram G, Frei A, et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: A prospective randomized study. *Arch Surg.* 1999 Dec;134(12):1309-16.
54. Wu C-, Meng HC, Mok K-, Kung S-, Lin S-, Liu W-, et al. Effect of total parenteral nutrition on the postoperative outcome in aged patients with gastric cancer. *Dig Surg.* 1995;12(3):164-70.
55. Han-Geurts IJ, Verhoef C, Tilanus HW. Relaparotomy following complications of feeding jejunostomy in esophageal surgery. *Dig Surg.* 2004;21(3):192-6.
56. Llaguna OH, Kim HJ, Deal AM, Calvo BF, Stitzenberg KB, Meyers MO. Utilization and morbidity associated with placement of a feeding jejunostomy at the time of gastroesophageal resection. *J Gastrointest Surg.* 2011 Oct;15(10):1663-9.
57. Bozzetti F, Gianotti L, Braga M, Di Carlo V, Mariani L. Postoperative complications in gastrointestinal cancer patients: The joint role of the nutritional status and the nutritional support. *Clin Nutr.* 2007 Dec;26(6):698-709.

Table 1a: Study Characteristics

Author	Year	Ref #	Intervention 1	Intervention 2	Intervention 3	Intervention 4	Subjects
Barlow	2011	33	Nil	SEN-J			121
Hyltander	2005	29	Nil	SEN-J	S-TPN		80
Heslin	1997	41	Nil	EEN-J			195
Page	2002	48	Nil	SEN-NJ			40
Cooper	2006	36	Nil	S-TPN			34
Kamei	2005	44	Nil	S-TPN			52
Wu	1995	54	Nil	S-TPN			51
Daly	1992	37	SEN-J	EEN-J			85
Farreras	2005	38	SEN-J	EEN-J			66
Giger	2007	39	SEN-J	EEN-J			46
Kenler	1996	32	SEN-J	EEN-J			50
Lobo	2006	47	SEN-J	EEN-J			120
Ryan	2009	31	SEN-J	EEN-J			70
Sakurai	2007	49	SEN-J	EEN-J			30
Senkal	1997	52	SEN-J	EEN-J			164
Senkal	1999	53	SEN-J	EEN-J			178
Han-Geurts	2007	40	SEN-J	SEN-NJ			150
Aiko	2003	30	SEN-J	S-TPN			39
Heylen	1987	42	SEN-J	S-TPN			20
Reynolds	1997	43	SEN-J	S-TPN			67
Klek	2008	45	SEN-NJ	EEN-NJ			196
Klek	2008	46	SEN-NJ	EEN-NJ	S-TPN	E-TPN	205
Sand	1997	50	SEN-NJ	S-TPN			29
Seike	2011	51	SEN-NJ	S-TPN			30
Braga	1995	35	SEN-NS	EEN-NS	S-TPN		77
Braga	2001	34	SEN-NS	S-TPN			257

Note: Nil = No Early Nutrition, SEN-J = Standard Enteral Nutrition – Jejunostomy, EEN-J = Enhanced Enteral Nutrition – Jejunostomy, SEN-NJ = Standard Enteral Nutrition – Nasojejunal, EEN-NJ = Enhanced Enteral Nutrition – Nasojejunal, SEN-NS = Standard Enteral Nutrition - Non-Specified, EEN-NS = Enhanced Enteral Nutrition - Non-Specified, S-TPN = Standard TPN, E-TPN = Enhanced TPN

Table 1b: Patient Characteristics

Author	Year	Ref #	Subjects	Mean age	% Male	% Esophageal Surgery	% Gastric Surgery	% Pancreatic Surgery	% with > 10% Weight Loss
Barlow	2011	33	121	NR	68.6	45	31	24	NR
Hyltander	2005	29	80	62.3	65.8	38	22	40	43
Heslin	1997	41	195	NR	60.0	14	37	49	NR
Page	2002	48	40	67.4	70.0	100	0	0	NR
Cooper	2006	36	34	68	81.5	100	0	0	NR
Kamei	2005	44	52	63.5	71.2	0	100	0	NR
Wu	1995	54	51	72.5	92.5	0	100	0	NR
Daly	1992	37	85	62.5	63.5	35	25	21	32
Farreras	2005	38	66	68	53.3	0	100	0	22
Giger	2007	39	46	61	58.7	0	26	74	54
Kenler	1996	32	50	63.6	74.3	37	6	37	NR
Lobo	2006	47	120	66	76.9	59	27	14	NR
Ryan	2009	31	70	63.9	88.4	100	0	0	18
Sakurai	2007	49	30	63	43.3	100	0	0	NR
Senkal	1997	52	164	65.7	NR	19	51	20	NR
Senkal	1999	53	178	65.5	64.9	17	38	13	NR
Han-Geurts	2007	40	150	NR	80.0	100	0	0	NR
Aiko	2003	30	39	65	84.6	100	0	0	NR
Heylen	1987	42	20	NR	NR	0	100	0	NR
Reynolds	1997	43	67	68	79.1	63	21	16	27
Klek	2008	45	196	62.2	62.3	0	62	38	19
Klek	2008	46	205	61.2	70.9	0	62	38	17
Sand	1997	50	29	NR	37.9	0	100	0	NR
Seike	2011	51	30	63.7	90.0	100	0	0	NR
Braga	1995	35	77	60.2	54.3	0	56	44	53
Braga	2001	34	257	63.5	54.1	10	47	43	35

Note: NR = Not Reported

Table 2: Overall Rate of Outcomes

Author	Year	Ref #	Patients	Mortality (%)	Anastomotic Failure (%)	Sepsis (%)	Pulmonary Infection (%)	Total Rate of Infection (%)
Barlow	2011	33	121	2.5	7.4	NR	14.0	40.5
Hyltander	2005	29	80	NR	NR	8.8	NR	18.8
Heslin	1997	41	195	2.6	7.2	1.0	5.1	22.1
Page	2002	48	40	0.0	NR	NR	NR	2.5
Cooper	2006	36	34	7.4	NR	3.7	NR	3.7
Kamei	2005	44	52	0.0	6.3	NR	NR	6.3
Wu	1995	54	51	0.0	12.5	NR	0.0	2.5
Daly	1992	37	85	2.4	NR	NR	NR	21.2
Farreras	2005	38	66	5.0	NR	0.0	3.3	18.3
Giger	2007	39	46	2.2	NR	NR	NR	37.0
Kenler	1996	32	50	2.9	NR	5.7	11.4	57.1
Lobo	2006	47	120	NR	16.7	5.6	34.3	51.9
Ryan	2009	31	70	0.0	3.8	13.2	22.6	39.6
Sakurai	2007	49	30	NR	16.7	NR	16.7	30.0
Senkal	1997	52	164	3.2	11.0	3.9	11.0	22.7
Senkal	1999	53	178	NR	7.8	5.2	8.4	17.5
Han-Geurts	2007	40	150	5.3	8.7	NR	37.3	55.3
Aiko	2003	30	39	0.0	0.0	NR	7.7	23.1
Heylen	1987	42	20	NR	0.0	NR	NR	15.0
Reynolds	1997	43	67	4.5	3.0	6.0	22.4	49.3
Klek	2008	45	196	1.1	3.8	NR	15.3	24.0
Klek	2008	46	205	2.0	13.7	3.9	23.9	52.2
Sand	1997	50	29	0.0	10.3	NR	13.8	27.6
Seike	2011	51	30	NR	43.3	NR	NR	NR
Braga	1995	35	77	0.0	NR	NR	NR	13.0
Braga	2001	34	257	2.7	13.6	1.2	3.5	24.5

Note: NR = Not Reported

Table 3: Direct and Indirect Comparisons

Outcome	Comparison	Data Ref #	# of Studies	OR	95% CI	I <sup>2</sup> (%)		Network OR	Network 95% CI
<b>Mortality</b>	Nil vs EN-J	1A	2	1.52	(0.39, 5.88)	41.7		1.44	(0.34, 5.10)
	Nil vs EN-NJ	1B	1	1.00	(0.02, 50.0)			0.44	(0.10, 1.59)
	Nil vs TPN	1C	3	0.36	(0.05, 2.44)	0		0.22	(0.04, 0.94)
	EN-J vs TPN	1D	2	0.58	(0.07, 4.55)	0		0.13	(0.02, 0.57)
	EN-NJ vs TPN	1E	2	1.00	(0.17, 5.88)	0		0.54	(0.14, 1.69)
	EN Stand vs EN Enh	1F	9	1.05	(0.44, 2.50)	0			
<b>Anastomotic failure</b>	Nil vs EN-J	2A	2	0.49	(0.20, 1.19)	27.8		0.43	(0.15, 1.14)
	Nil vs EN-NJ	2B	0					0.75	(0.29, 1.97)
	Nil vs TPN	2C	2	1.11	(0.26, 4.76)	0		0.67	(0.30, 1.46)
	EN-J vs TPN	2D	3	1.00	(0.14, 7.14)	0		1.57	(0.63, 3.90)
	EN-NJ vs TPN	2E	3	0.91	(0.47, 1.79)	0		0.88	(0.47, 1.63)
	EN Stand vs EN Enh	2F	7	0.78	(0.48, 1.25)	0			
<b>Sepsis</b>	Nil vs EN-J	3A	2	1.02	(0.10, 10.0)	0		0.31	(0.05, 1.68)
	Nil vs EN-NJ	3B	0					3.39	(0.51, 22.6)
	Nil vs TPN	3C	2	3.70	(0.82, 16.7)	76.1		1.99	(0.62, 5.52)
	EN-J vs TPN	3D	2	7.69	(1.39, 50.0)	0		6.38	(1.48, 25.1)
	EN-NJ vs TPN	3E	1	0.62	(0.14, 2.63)			0.59	(0.11, 2.59)
	EN Stand vs EN Enh	3F	7	0.98	(0.49, 1.92)	0			
<b>Pulmonary Infection</b>	Nil vs EN-J	4A	2	0.35	(0.15, 0.84)	0		0.33	(0.13, 0.74)
	Nil vs EN-NJ	4B	0					0.44	(0.15, 1.19)
	Nil vs TPN	4C	1	1.00	(0.02, 50.0)			0.40	(0.13, 1.11)
	EN-J vs TPN	4D	2	1.30	(0.46, 3.57)	0		1.21	(0.62, 2.37)
	EN-NJ vs TPN	4E	2	0.89	(0.49, 1.67)	0		0.90	(0.52, 1.55)
	EN Stand vs EN Enh	4F	9	0.92	(0.64, 1.32)	0			
<b>Total Infection</b>	Nil vs EN-J	5A	3	0.56	(0.35, 0.91)	82.1		0.68	(0.44, 1.07)
	Nil vs EN-NJ	5B	1	3.13	(0.12, 100)			0.82	(0.43, 1.49)
	Nil vs TPN	5C	4	2.86	(1.05, 7.69)	51		1.04	(0.57, 1.89)
	EN-J vs TPN	5D	4	2.63	(1.35, 5.26)	50.4		1.54	(0.94, 2.52)
	EN-NJ vs TPN	5E	2	0.83	(0.50, 1.41)	0		1.29	(0.83, 2.04)
	EN Stand vs EN Enh	5F	12	0.67	(0.51, 0.88)	24.3			

Figure 1: Quorum Diagram





Figure 2: Network Diagram for Total Rate of Infection Outcome



Note: Numbers represent the number of studies that made each comparison

Figure 3: Risk of Bias Diagram




Figure 4: Plots of Meta-Analysis Odds Ratios for Each Outcome

